Avance (2021a). NPV vs rNPV. Disponible en: https://avance.ch/download/npv-vs-rnpv/.
Avance (2021b). Discount rates in drug development. Disponible en: https://avance.ch/download/discount-rates-in-pharma-and-biotech/.
Biotechnology Innovation Organization (2021). Clinical development success rates and contributing factors 2011–2020. Informa Pharma Intelligence, QLS advisors.
Black, F. y M. Scholes (1973). The Pricing of Options and Corporate Liabilities. Journal of Political Economy, 81(3), 637–654. www.jstor.org/stable http://www.jstor.org/stable/1831029.
Bogdan, B. y R. Villiger (2010). Valuation in Life Sciences. 3ª edición. Berlín, Heidelberg: Springer.
Chance, D.M. y P.P. Peterson (2002). Real Options and Investment Valuation. The Research Foundation of the Association for Investment Management and Research (actualmente Chartered Financial Analyst Institute).
Clinical Research (2019). Cost of Clinical Trials: A Breakdown (Infographic). Disponible en: www.clinicalresearch.io/blog/industry-trends/cost-of-clinical-trial-breakdown.
Cook, A. (2016). Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them.. 2ª edición. Londres: Gower.
Copeland, T. y V. Antikarov (2001). Real Options – A Practitioners’ Guide. Nueva York: Texere.
Schlander, M. et al. (2021). How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics, 39(11), págs. 1243-1269. doi.org/10.1007/s40273-021-01065-y.